Bristol-Myers Squibb and Otsuka Pharmaceutical Co. Ltd


FLORENCE, Italy - Results Presented at the Annual Congress of the World Psychiatric Association (WPA) ABILIFY(R) (aripiprazole), when used in combination with lithium or valproate, is a generally well-tolerated long-term treatment for patients with Bipolar I Disorder, who are partially non-responsive to lithium or valproate monotherapy.(1) The data presented at the annual congress for the World Psychiatric Association (WPA) report a favourable long-term safety profile for ABILIFY in combination with lithium or valproate.(1) Professor Eduard Vieta, lead study investigator and Professor of Psychiatry and Director of the Bipolar Disorders Programme of the Hospital Clinic at the University of Barcelona, Spain, said "As a doctor, I value data on safety, tolerability and efficacy as extremely important.
Older News
S M T W T F S
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
Copyright© 2010 The Gaea Times